Insight Molecular Diagnostics
IMDX
90 hedge funds and large institutions have $323M invested in Insight Molecular Diagnostics in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 34 reducing their positions, and 11 closing their positions.
115% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $607K
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
15% more capital invested
Capital invested by funds: $282M → $323M (+$41.1M)
3% more funds holding
Funds holding: 87 → 90 (+3)
0.08% more ownership
Funds ownership: 3.07% → 3.15% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$3.63M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.36M |
| 3 |
PGM
Parian Global Management
Pound Ridge,
New York
|
+$1.71M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
+$1.38M |
| 5 |
Goldman Sachs
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.54M |
| 2 |
BlackRock
New York
|
-$1.16M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.14M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.07M |
| 5 |
Barclays
London,
United Kingdom
|
-$486K |
IMDX Hedge Fund Activity: Q2 2021 in Review
90 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2021, worth a combined $323M — up 15% from $282M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IMDX positions and 11 closed out — a net gain of 3 holders — while 26 added to existing stakes and 34 trimmed.
The largest buyer was Defender Capital, adding an estimated $3.63M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $1.54M sold.
- 90 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2021, up from 87 in Q1 2021.
- Funds reported $323M of Insight Molecular Diagnostics stock for Q2 2021, up 15% quarter-over-quarter.
- 14 funds opened new Insight Molecular Diagnostics positions in Q2 2021 and 11 closed out, a net change of +3 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2021 was Defender Capital, an estimated $3.63M added.
- The largest Insight Molecular Diagnostics seller in Q2 2021 was Soleus Capital Management, an estimated $1.54M sold.
Based on aggregated 13F filings for Q2 2021.